Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

24.32 -0.57 (-2.27%)
Streaming Delayed Price Updated: 1:14 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX
The medical sector is usually of interest during economic uncertainty, especially when it leads to heightened stock market volatility. 
Via Talk Markets
Topics Stocks / Equities
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals.
PACIRA BIOSCIENCES INC has a stellar value proposition. NASDAQ:PCRX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate
Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery. 
Via Benzinga
Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued.
Consider PACIRA BIOSCIENCES INC as a top value stock. NASDAQ:PCRX shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced. 
Via Chartmill
What 8 Analyst Ratings Have To Say About Pacira BioSciences
Via Benzinga
6 Analysts Assess Pacira BioSciences: What You Need To Know
Via Benzinga
Decoding 6 Analyst Evaluations For Pacira BioSciences
Via Benzinga
Evaluating Pacira BioSciences: Insights From 8 Financial Analysts
Via Benzinga
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
PACIRA BIOSCIENCES INC (NASDAQ:PCRX), an undervalued stock with good fundamentals. 
Via Chartmill
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
Via Benzinga
Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain
Pacira launches a new iovera° Smart Tip for chronic back pain relief, offering an alternative to radiofrequency ablation with promising study results. 
Via Benzinga
Exposures Product Safety
Investors seeking growth at a reasonable cost should explore NASDAQ:PCRX.
Investors should take note ofPACIRA BIOSCIENCES INC (NASDAQ:PCRX), a growth stock that remains attractively priced. 
Via Chartmill
Insights into Pacira BioSciences's Upcoming Earnings
Via Benzinga
Expert Ratings For Pacira BioSciences
Via Benzinga
Where Pacira BioSciences Stands With Analysts
Via Benzinga
Expert Ratings For Pacira BioSciences
Via Benzinga
NASDAQ:PCRX: good value for what you're paying.
For those who appreciate value investing, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is a compelling option with its solid fundamentals. 
Via Chartmill
Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path
Pacira BioSciences faces a significant setback as the U.S. District Court invalidates its key patent on Exparel, leading to a 40% stock drop. Exparel, crucial to Pacira's revenue, is now vulnerable,... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
JetBlue Airways, B. Riley Financial, Hawaiian Electric And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
In a market where value is scarce, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
PCRX Stock Earnings: Pacira BioSciences Beats EPS, Beats Revenue for Q2 2024
PCRX stock results show that Pacira BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
3 Biotech Stocks to Buy on the Dip: July 2024
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip. 
Via InvestorPlace
NASDAQ:PCRX, an undervalued stock with good fundamentals.
Despite its impressive fundamentals, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) remains undervalued. 
Via Chartmill
In a market where value is scarce, NASDAQ:PCRX offers a refreshing opportunity with its solid fundamentals.
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
Top 5 Health Care Stocks That May Explode In July
Via Benzinga
This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights
Via Benzinga
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
When you look at PACIRA BIOSCIENCES INC (NASDAQ:PCRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.